• 1
    Andrew M, Marzinotto V, Massicotte P et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr. Res. 1994; 35: 7883.
  • 2
    Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle APP. Dosing and monitoring of enoxaparin (LMWH) therapy in children. Br. J. Haematol. 2010; 149: 734738.
  • 3
    Massicotte P, Adams M, Marzinotto V et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J. Pediatr. 1996; 128: 313318.
  • 4
    Newall F , Monagle P , Savioa H , Campbell J , Browne M , Greenway A , eds. Anticoagulation Clinics for Children Achieve Improved Warfarin Management. Birmingham, UK: International Society of Thrombosis and Haemostasis, 2003.
  • 5
    Raffini L, Huang Y, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124: 10011008.
  • 6
    Newall F, Bauman M. Point-of-care antithrombotic monitoring in children. Thromb. Research. 2005; 21: 5361.
  • 7
    Andrew M, Marzinotto V, Brooker L et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb. Hemost. 1994; 71: 265269.
  • 8
    Bonduel M. Oral anticoagulation therapy in children. Thromb. Res. 2006; 118: 8594.
  • 9
    Bonduel M, Sciuccati G, Hepner M et al. Acenocoumarol therapy in pediatric patients. J. Thromb. Haemost. 2003; 1: 17401743.
  • 10
    Monagle P, Adams M, Mahoney M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res. 2000; 47: 763766.
  • 11
    Newall F, Barnes C, Savioa H, Campbell J, Monagle P. Warfarin therapy in children requiring long term total parenteral nutrition (TPN). Pediatrics 2003; 112: e386.
  • 12
    Newall F, Savoia H, Campbell J, Monagle P. Anticoagulation clinics for children achieve improved warfarin management. Thromb. Res. 2004; 114: 59.
  • 13
    Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94: 30073014.
  • 14
    Bauman M, Black L, Massicotte P et al. Accuracy of the CoaguChek XS for point-of-care international normalized ratio (INR) measurement in children requiring warfarin. Thromb. Haemost. 2008; 99: 10971103.
  • 15
    Christensen TD, Attermann J, Hjortdal VE, Maegaard M, Hasenkam JM. Self-management of oral anticoagulation in children with congenital heart disease. Cardiol. Young 2001; 11: 269276.
  • 16
    Greenway A, Ignjatovic V, Summerhayes R et al. Point-of-care monitoring of oral anticoagulation therapy in children – comparison of the CoaguChek XS system with venous INR and venous INR using an international reference thromboplastin preparation rTF/95). Thromb. Haemost. 2009; 102: 159165.
  • 17
    Ignjatovic V, Barnes C, Newall F, Hamilton S, Burgess J, Monagle P. Point of care monitoring of oral anticoagulant therapy in children: comparison of Coaguchek (TM) and Thrombotest methods with venous International Normalised Ratio. Thromb. Haemost. 2004; 92: 734737.
  • 18
    Marzinotto V, Monagle P, Chan A et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr. Cardiol. 2000; 21: 347352.
  • 19
    Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J. Pediatr. 1995; 127: 389394.
  • 20
    Newall F , Johnston L , Monagle P , eds. Optimising Anticoagulant Management Strategies Through the Use of Validated Educational Interventions. Sydney, Australia: International Society of Thrombosis and Haemostasis, 2005.
  • 21
    Newall F, Monagle P, Johnston L. Home INR monitoring of oral anticoagulant therapy in children using the CoaguChekTM S point-of-care monitor and a robust education program. Thromb. Res. 2006; 118: 587593.
  • 22
    Hawthorne G. Introduction to Health Program Evaluation. Melbourne: Centre for Health Program Evaluation, The University of Melbourne; 2000.
  • 23
    Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb. Hemost. 1995; 74: 415425.
  • 24
    Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165172.
  • 25
    Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 19882005.
  • 26
    Monagle P, Barnes C, Ignjatovic V et al. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb. Haemost. 2006; 95: 362372.
  • 27
    Barnes C, Newall F, Cameron F, Wong P, Monagle P. Reduced bone density in children on long-term warfarin. Pediatr. Res. 2005; 57: 578581.
  • 28
    Newall F, Monagle P, Johnston L. Patient understanding of warfarin therapy: a review of education strategies. Hematology 2005; 10: 437442.
  • 29
    Newall F, Johnston L, Monagle P. Optimising anticoagulant education in the paediatric setting using a validated model of education. Patient Educ. Couns. 2008; 73: 384388.
  • 30
    Mitchell L, Na G, Male C, Kenet G, Monagle P, Nowak-Gottl U. Definition of clinical efficacy and safety outcomes for clinical trials in deep vein thrombosis and pulmonary embolism in children. J. Thromb. Haemost. 2011; 9: 18561858.
  • 31
    Jones S, Monagle P, Manias E, Bruce A, Newall F. Quality of life assessment in children requiring long-term oral anticoagulant therapy. XXII Congress of the International Society of Thrombosis and Haemostasis; Kyoto, Japan: Journal of Thrombosis and Haemostasis; 2011.
  • 32
    Jones S, Newall F, Monagle P, Manias E. Assessing outcome measures of oral anticoagulation management in children. Thromb. Res. 2011; 127: 7580.